Hjem › Bronkiekræft › Texas
Bronkiekræft kliniske forsøg i Texas
5 studier for Bronkiekræft søger deltagere på steder i Texas.
Byer i Texas
Officiel studietekst (engelsk)
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- og 1 flere
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06128551A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- USO - Texas Oncology, Austin
- William Beaumont Army Medical Center, Fort Bliss
- Houston Methodist Hospital, Houston
- og 3 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT06119581Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
- Texas Oncology, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. sep. 2026 · NCT07185997A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- UT Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RekruttererFase 1/2
Alder 12 og opefter · Alle køn · Opdateret 27. maj 2026 · NCT03093116Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 19. feb. 2026 · NCT02984761Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.